Becton Dickinson stock holds steady ahead of September ex-dividend date
Published on 09/08/2026 at 14:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Becton, Dickinson and Company stock (ISIN US0718131099) is trading near its current analyst average target price as investors prepare for a 1.05 USD per-share dividend that is scheduled to go ex-dividend on September 9, 2026.moomoo As of September 8, 2026, market data show the stock opening at 184.78 USD on the New York Stock Exchange, only slightly below an average analyst target of 187.67 USD.MarketBeat
Dividend of 1.05 USD per share in focus
According to moomoo, Becton Dickinson will trade ex-dividend on September 9, 2026, with shareholders of record on that date entitled to receive a cash dividend of 1.05 USD per share on September 30, 2026. This quarterly payment corresponds to an annualized dividend of 4.20 USD per share and implies a dividend yield of about 2.3 percent based on the recent share price.MarketBeat For income-oriented investors, the combination of a scheduled cash payout at the end of September and a yield above 2 percent offers a tangible near-term return signal.
MarketBeat notes that the company’s dividend payout ratio stands at 126.51 percent of reported earnings, which is high in absolute terms and underlines that the dividend policy leans on adjusted earnings power and cash flow rather than purely on GAAP net income. The same source reports that the upcoming dividend was declared for payment on September 30, 2026, aligned with the ex-dividend and record dates in early September 2026.MarketBeat That schedule reinforces the dividend as the immediate calendar catalyst for Becton Dickinson stock.
Recent earnings beat and guidance
Beyond the dividend, the latest quarterly results provide important context for how Becton Dickinson is currently valued. In its most recent reported quarter, ended in fiscal 2026 and released on August 6, 2026, the company generated earnings per share of 3.23 USD, beating the average analyst consensus of 3.14 USD by 0.09 USD per share.MarketBeat Revenue in that quarter reached 4.98 billion USD, compared with expectations of 4.89 billion USD, meaning reported revenue came in about 1.8 percent above consensus.MarketBeat
The same earnings report shows that Becton Dickinson achieved year-over-year revenue growth of 5.4 percent in that quarter, underscoring that demand for its medical instruments and related products continues to expand at a mid-single-digit pace.MarketBeat The company posted a net margin of 4.52 percent and a return on equity of 14.79 percent, indicating that while headline profitability remains modest after all costs, the underlying capital efficiency is significantly stronger.MarketBeat This mix of better-than-expected earnings per share and revenue, combined with decent returns on equity, is a key reason why the stock is holding close to its average target price.
Looking ahead, Becton Dickinson has set guidance for fiscal year 2026 earnings at a range of 12.62 to 12.72 USD per share.MarketBeat Analysts covering the stock currently forecast full-year earnings per share of 12.67 USD, essentially in the middle of the company’s own guidance band.MarketBeat The alignment between internal guidance and external expectations reduces the risk of major surprise revisions and gives investors a clearer earnings baseline to assess whether the present valuation and dividend yield look sustainable.
Analyst views and valuation context
The analyst community has a balanced view on Becton Dickinson at the moment. According to MarketBeat, eight research analysts rate the stock as a Buy, eight as a Hold and one as a Sell, resulting in an overall consensus rating of Hold. The same data set points to an average target price of 187.67 USD, only around 1.6 percent above the recent opening level of 184.78 USD.MarketBeat This narrow gap suggests that, in aggregate, analysts see limited near-term upside but also no significant downside from current levels, assuming the company delivers on its guidance.
The modest premium of the target price over the current trading level also highlights the importance of dividend income in the total return equation. With an annualized dividend of 4.20 USD per share and a yield of about 2.3 percent, a significant part of the expected shareholder return is likely to come from ongoing cash distributions rather than from rapid price appreciation.MarketBeat For investors, that means the stock is positioned more as a defensive healthcare holding with income characteristics than as a high-growth momentum play.
One risk factor visible in the numbers is the comparatively low net margin of 4.52 percent in the latest quarter.MarketBeat This indicates that rising costs, pricing pressure or investment spending are constraining bottom-line profitability even as revenue grows at 5.4 percent year-over-year.MarketBeat If margin compression were to intensify, it could challenge the sustainability of a payout ratio above 120 percent and force management to recalibrate the balance between dividend growth, debt reduction and reinvestment.
Medical devices support long-term demand
Becton Dickinson is best known for its broad portfolio of medical devices and supplies used in hospitals, laboratories and outpatient care, including products such as syringes, infusion systems and diagnostic instruments. These products underpin recurring demand in global healthcare systems, which helps explain the company’s ability to deliver steady mid-single-digit revenue growth even in a mature industry.MarketBeat For investors, the scale and diversification of the portfolio provide a structural buffer against short-term volatility in individual product lines.
Stock price and market data
Market data compiled by MarketBeat indicate that Becton Dickinson stock opened at 184.78 USD on September 8, 2026, on the New York Stock Exchange. The same data show that the stock’s dividend yield, based on the annualized 4.20 USD per-share dividend, stands at approximately 2.3 percent at this price level.MarketBeat With the share price trading only slightly below the 187.67 USD average analyst target, the current valuation reflects both the recent earnings beat and the upcoming ex-dividend date.
Becton Dickinson stock key data
- Company: Becton, Dickinson and Company
- ISIN: US0718131099
- Ticker: BDX
- Trading venue: NYSE
- Price (as of September 8, 2026): 184.78 USD
- Market capitalization: [value] USD (as of September 8, 2026)
- Sector / Industry: Health Care / Medical Instruments
- Index membership: S&P 500
- Next earnings date: [Month D, YYYY]
